ASTEPRO® ALLERGY ANTIHISTAMINE NASAL SPRAY
ASTEPRO® ALLERGY ANTIHISTAMINE NASAL SPRAY
Astepro allergy is now approved. Previously only available as Rx. The first1 and only2 OTC antihistamine nasal spray3
OVERVIEW
Proven to relieve nasal congestion—the most bothersome symptom for many allergy sufferers4—as well as runny nose, itchy nose, and sneezing5-8
In clinical trials, Astepro significantly improved all 4 TNSS components5-8
Results of a 2-week, placebo-controlled, double-blind study comparing azelastine HCl 0.15% nasal spray, 2 sprays per nostril once daily, with placebo in patients with SAR (n=266 for patients receiving Astepro and n=266 for patients receiving placebo). The study was conducted in the United States during Texas Mountain Cedar season. The primary efficacy variable was change from baseline in 12-hour reflective TNSS over the entire 2 weeks of treatment. TNSS consisted of nasal congestion, itchy nose, runny nose, and sneezing, scored on a 4-point (0 to 3) scale with a maximum possible daily score of 24.
SAR, seasonal allergic rhinitis; TNSS, Total Nasal Symptom Score.
Astepro Allergy is the same as prescription Astepro (azelastine HCl) 0.15% Nasal Spray, 205.5 mcg (Rx approval in 2009)3,9-11
It is different than both Astelin® (azelastine HCl) Nasal Spray 137 mcg (Rx approval in 1996), and Astepro (azelastine HCl) 0.10% Nasal Spray 137 mcg (Rx approval in 2008).9-11
Astepro Allergy has:
- The same prescription strength as Astepro 0.15% and 50% higher concentration of azelastine HCl than prescription Astelin3,9,11
- The same improved taste profile as prescription Astepro3,6
- Once or twice daily dosing3,*
* For adults and children 12 years and older, Astepro Allergy can be used once daily (2 sprays in each nostril) OR twice daily (1 or 2 sprays in each nostril every 12 hours). Patients should not use more than 4 sprays per nostril in a 24 hour period. For children 6 years to 11 years old, dosing is 1 spray in each nostril every 12 hours. These patients should not use more than 2 sprays in each nostril in a 24 hour period.
PROVIDES UP TO 24 HOUR RELIEF OF3:
DIRECTIONS
DIRECTIONS3
Read the User Guide for how to:
- prime the bottle before first use
- prime bottle again if not used for 3 or more days
- use the spray
- clean the spray nozzle if it gets clogged
Adults and children 12 years and older |
This product may be used either once or twice a day.
|
Children 6 years to 11 years |
|
Children under 6 years |
Do not use |
INGREDIENTS
INGREDIENTS3
Active ingredient (in each spray):
Azelastine hydrochloride 0.15% (205.5 mcg)
Inactive ingredients:
Benzalkonium chloride, edetate disodium, hypromellose, purified water, sodium citrate, sorbitol, sucralose
WARNINGS FOR PATIENTS
WARNINGS FOR PATIENTS3
Only for use in the nose. Do not spray in eyes or mouth.
Do not use if you have ever had an allergic reaction to this product or any of its ingredients.
Ask a doctor before use if you:
- have had recent nose ulcers or nose surgery
- have had a nose injury that has not healed
When using this product:
- drowsiness may occur
- avoid alcoholic drinks
- alcohol, sedatives, and tranquilizers may increase drowsiness
- be careful when driving a motor vehicle or operating machinery
- you may get a bitter taste in your mouth. To help avoid this, tilt your head downward while spraying
- nasal discomfort or sneezing may occur right after use
- do not share this bottle with anyone else as this may spread germs
Stop use and ask a doctor if:
- an allergic reaction, such as a skin rash, to this product occurs
- you have severe or frequent nosebleeds
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
OTHER INFORMATION FOR PATIENTS3
Store between 20° to 25°C (68° to 77°F). Protect from freezing.
Keep the carton and the enclosed User Guide for important information.
Do not use if tape printed with “sealed for your protection” on top and bottom carton flaps is not intact.
References:
-
FDA approves a nasal antihistamine for nonprescription use. Approval is a first-in-class and was enabled by the prescription to nonprescription switch process. News release. FDA; June 17, 2021. Accessed March 2, 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-nasal-antihistamine-nonprescription-use.
-
Data on file. Bayer. IRI data. Only OTC AH.
-
NDA 213872.
-
Stewart M, Ferguson BJ, Fromer L. Epidemiology and burden of nasal congestion. Int J Gen Med. 2010;3:37-45.
-
Data on file. Bayer. MP440 CSR. Symptom scores.
-
van Bavel J, Howland WC, Amar NJ, Wheeler W, Sacks H. Efficacy and safety of azelastine 0.15% nasal spray administered once daily in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2009;30(5):512-518.
-
Shah S, Berger W, Lumry W, La Force C, Wheeler W, Sacks H. Efficacy and safety of azelastine 0.15% nasal spray and azelastine 0.10% nasal spray in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2009;30(6):628-633. doi:10.2500/aap.2009.30.3296
-
Howland WC, Amar NJ, Wheeler W, Sacks H. Efficacy and safety of azelastine 0.15% nasal spray administered once daily in patients with allergy to Texas mountain cedar pollen. Int Forum Allergy Rhinol. 2011;1(4):275-279. doi:10.1002/alr.20065
-
Astepro®. Prescribing information. Meda Pharmaceuticals Inc; 2018.
-
US Department of Health and Human Services. Pediatric Postmarketing Pharmacovigilance and Drug Utilization Review. November 3, 2016. Accessed April 7, 2022. https://www.fda.gov/media/100100/download.
-
Astelin. Prescribing information. Meda Pharmaceuticals Inc; 2014.
-
Watts AM, Cripps AW, West NP, Cox AJ. Modulation of allergic inflammation in the nasal mucosa of allergic rhinitis sufferers with topical pharmaceutical agents. Front Pharmacol. 2019;10:294:1-22. doi:10.3389/fphar.2019.00294
-
Flonase® Drug Facts Label. NDA205434.
-
Nasacort® Drug Facts Label. NDA020468.
-
Rhinocort® Drug Facts Label. NDA020746.